Affimed

AFMDPhase 2

Affimed is a German biopharmaceutical company focused on revolutionizing cancer treatment by engaging the innate immune system. Its core technology, the Redirected Optimized Cell Killing (ROCK®) platform, enables the creation of innate cell engagers (ICE®) that are designed to be highly potent and have a favorable safety profile. The company's most advanced programs, including AFM13 and AFM24, are in clinical development for various lymphomas and solid tumors, respectively, with key partnerships established with Genentech and Roivant to accelerate development and commercialization. As a publicly traded company, Affimed is strategically positioned to advance its pipeline and validate its innovative approach in immuno-oncology.

Employees

150-200

Focus

Biotech

AFMD · Stock Price

USD 0.18+0.00 (+0.00%)

Historical price data

AI Company Overview

Technology Platform

The ROCK® (Redirected Optimized Cell Killing) platform generates tetravalent, bispecific innate cell engagers (ICE®) that are designed to recruit and activate natural killer cells and macrophages to kill tumor cells.

Pipeline Snapshot

9 drugs in pipeline

Drug	Indication	Stage
AFM13	Hodgkin Lymphoma	Phase 2
AFM13	Peripheral T Cell Lymphoma	Phase 2
AFM24 + SNK01	Squamous Cell Carcinoma of Head and Neck	Phase 1/2
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Advanced Solid Tumor	Phase 1/2
14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320 mg AFM24 + 480 mg A...	Advanced Solid Tumor	Phase 1/2

Opportunities

Affimed's primary growth opportunity lies in successfully commercializing AFM13 for PTCL, a high-need orphan indication, which would establish its first revenue stream.

The broad potential of its ICE® platform is validated by the Genentech partnership for AFM24 in large solid tumor markets, offering significant milestone and royalty upside.

The company is well-positioned to explore additional partnerships for its preclinical pipeline and platform technology.

Risk Factors

Key risks include clinical trial failures, particularly for the pivotal AFM13 study, which would severely impact valuation.

The company faces intense competition in the bispecific antibody space from larger, well-funded players.

As a pre-revenue company, Affimed remains dependent on capital markets and partnership payments to fund operations, risking future dilution.

Competitive Landscape

Affimed competes in the bispecific antibody arena but differentiates by exclusively engaging innate immune cells (NK cells/macrophages) rather than T-cells. Its main competitors are companies developing T-cell engagers (e.g., Amgen, Regeneron) and other emerging NK cell engager platforms (e.g., Sanofi, Innate Pharma). Affimed's first-mover clinical data with a tetravalent NK cell engager and its strategic Genentech partnership are key differentiators.